The 20-Year Voyage Aboard the Journal of Alzheimer's Disease: Docking at 'Type 3 Diabetes', Environmental/Exposure Factors, Pathogenic Mechanisms, and Potential Treatments

J Alzheimers Dis. 2018;62(3):1381-1390. doi: 10.3233/JAD-170829.

Abstract

The Journal of Alzheimer's Disease (JAD), founded in 1998, played a pivotal role in broadening the field of research on Alzheimer's disease (AD) by publishing a diverse range of clinical, pathological, molecular, biochemical, epidemiological, experimental, and review articles from its birth. This article recounts my own journey as an author who contributed articles to JAD over the 20 years of the journal's existence. In retrospect, it seems remarkable that a considerable body of work that originated from our group marks a trail that began with studies of vascular, stress, and mitochondrial factors in AD pathogenesis, exploded into the concept of 'Type 3 Diabetes', and continued with the characterization of how environmental, exposure, and lifestyle factors promote neurodegeneration and which therapeutic strategies could reverse the neurodegeneration cascade.

Keywords: Ceramides; Type 3 diabetes; dementia; diabetes; insulin resistance; neuroinflammation; nitrosamines; obesity; streptozotocin; vascular steatohepatitis.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Alzheimer Disease / epidemiology
  • Alzheimer Disease / physiopathology*
  • Alzheimer Disease / therapy*
  • Animals
  • Diabetes Mellitus / epidemiology
  • Diabetes Mellitus / physiopathology
  • Diabetes Mellitus / therapy
  • Humans
  • Periodicals as Topic